| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S9283 R32206 |
Artama (Valproate) (Controls exposed to Lamotrigine, sick), 2013 | Caesarean section | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.96 [0.62;1.47] C excluded (control group) |
126/706 32/173 | 158 | 706 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9284 R32218 |
Artama (Valproate) (Controls unexposed, disease free), 2013 | Caesarean section | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.16 [0.96;1.42] excluded (control group) |
126/706 114,791/721,948 | 114,917 | 706 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9285 R32230 |
Artama (Valproate) (Controls unexposed, sick), 2013 | Caesarean section | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 0.93 [0.73;1.18] | 126/706 331/1,800 | 457 | 706 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9450 R33184 |
Rihtman (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2013 | Cesarean section | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Controls: epilepsy indication |
1.80 [0.53;6.08] C excluded (control group) |
7/29 6/40 | 13 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9451 R33219 |
Rihtman (Valproate) (Controls unexposed, NOS) (Mixed indications), 2013 | Cesarean section | at least 1st trimester excluded | prospective cohort | unexposed (general population or NOS) | Adjustment: No |
3.74 [0.99;14.12] C excluded (exposition period) |
7/29 4/51 | 11 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9432 R33123 |
Borthen (Valproate) (Controls exposed to Lamotrigine, sick), 2010 | Caesarean | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.89 [0.55;1.45] C excluded (control group) |
37/215 44/233 | 81 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9434 R33131 |
Borthen (Valproate) (Controls unexposed, disease free), 2010 | Caesarean | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.70 [1.20;2.40] excluded (control group) |
37/215 51,806/362,302 | 51,843 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9436 R33139 |
Borthen (Valproate) (Controls unexposed, sick), 2010 | Caesarean | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 0.94 [0.65;1.37] C | 37/215 337/1,863 | 374 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9300 R32376 |
Endo (Valproate) (Controls unexposed, disease free), 2004 | Cesarean section | at least 1st trimester | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
0.87 [0.05;16.27] C excluded (control group) |
0/5 74/656 | 74 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9301 R32391 |
Endo (Valproate) (Controls unexposed, sick), 2004 | Cesarean section | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.11 [0.00;14.76] C | 0/5 0/1 | 0 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9308 R32419 |
Jäger-Roman (Valproate), 1986 | Caesarean section | at least 1st trimester excluded | prospective cohort | unexposed (general population or NOS) | Adjustment: No |
5.40 [1.38;21.12] C excluded (exposition period) |
4/14 8/116 | 12 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 0.93 [0.76;1.14] | 831 | 926 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Valproate) (Controls unexposed, sick; 2: Valproate) (Controls unexposed, sick; 3: Valproate) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9300, 9432, 9434, 9283, 9284, 9450